Verona Pharma plc Verona Pharma Plc: Tr-1: Standard Form For Notification Of Major Holdings
July 30 2020 - 5:52AM
UK Regulatory
TIDMVRP
LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) --
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the
relevant issuer and to the FCA in Microsoft Word format
if possible) (i)
-----------------------------------------------------------------------------------------------------------------------------------------
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are attached
(ii) : Verona Pharma plc
------------------------------------------------------------------------ ---------------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
-----------------------------------------------------------------------------------------------------------------------------------------
Non-UK issuer
---------------------------------------------------------------------------------------------------------------------- -----------------
2. Reason for the notification (please mark the appropriate
box or boxes with an "X")
-----------------------------------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
---------------------------------------------------------------------------------------------------------------------- -----------------
An acquisition or disposal of financial instruments
---------------------------------------------------------------------------------------------------------------------- -----------------
An event changing the breakdown of voting rights
---------------------------------------------------------------------------------------------------------------------- -----------------
Other (please specify) (iii) :
---------------------------------------------------------------------------------------------------------------------- -----------------
3. Details of person subject to the notification obligation
(iv)
Abingworth LLP
Name Abingworth Bioventures VI LP
City and country of registered office (if applicable) London, UK
4. Full name of shareholder (s) (if different from
3.) (v)
-----------------------------------------------------------------------------------------------------------------------------------------
State Street (Nominees) Limited (as nominee for Abingworth
Name Bioventures VI LP)
------------------------------------------------------------------------ ---------------------------------------------------------------
City and country of registered office (if applicable) London, UK
------------------------------------------------------------------------ ---------------------------------------------------------------
5. Date on which the threshold was crossed or reached
(vi) : 22/07/2020
------------------------------------------------------------------------ ---------------------------------------------------------------
6. Date on which issuer notified (DD / MM / YYYY): 30/07/2020
------------------------------------------------------------------------ ---------------------------------------------------------------
7. Total positions of person (s) subject to the notification
obligation
-----------------------------------------------------------------------------------------------------------------------------------------
% of voting rights
% of voting rights through financial Total number of
attached to shares instruments (total of 8.B Total of both in% voting rights of
(total of 8. A) 1 + 8.B 2) (8.A + 8.B) issuer (vii)
--------------------------------------------------- ------------------- ------------------------- ----------------- -----------------
Resulting situation on the date on which threshold
was crossed or reached 4.75 4.75 414,278,294
--------------------------------------------------- ------------------- ------------------------- ----------------- -----------------
Position of previous notification (if
applicable) 6.90 6.90
--------------------------------------------------- ------------------- ------------------------- ----------------- -----------------
8. Notified details of the resulting situation on
the date on which the threshold was crossed or reached
(viii)
-----------------------------------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
-----------------------------------------------------------------------------------------------------------------------------------------------------
Class / type of
shares
ISIN code (if possible) Number of voting rights (ix) % of voting rights
--------------------------------
Direct Indirect Direct Indirect
(Art. 9 of Directive (Art. 10 of Directive (Art. 9 of Directive (Art. 10 of Directive
2004/109 / EC) (DTR5.1) 2004/109 / EC) (DTR5.2.1) 2004/109 / EC) (DTR5.1) 2004/109 / EC) (DTR5.2.1)
------------------------------- ------------------------ -------------------------- --------------------------------- --------------------------
Verona Pharma plc
GB00BYW2KH80
5p Ords 1 less than 0.01
-------------------------------- ------------------------ -------------------------- --------------------------------- --------------------------
Verona Pharma plc US9250501064
ADSs 19,660,000 4.75
-------------------------------- ------------------------ -------------------------- --------------------------------- --------------------------
SUBTOTAL 8. A 19,660,001 4.75
-------------------------------- ---------------------------------------------------- -------------------------------------------------------------
B 1: Financial Instruments according to Art. 13 (1)
(a) of Directive 2004/109 / EC (DTR5.3.1.1 (a))
-----------------------------------------------------------------------------------------------------------------------------------------------------
Type of financial instrument Expiration Exercise / Number of voting rights % of voting rights
date (x) Conversion Period (xi) that may be acquired if
the instrument is
exercised / converted.
-------------------------------- ------------------------ -------------------------- --------------------------------- --------------------------
SUBTOTAL 8. B 1
-------------------------- --------------------------------- --------------------------
B 2: Financial Instruments with similar economic effect
according to Art. 13 (1) (b) of Directive 2004/109
/ EC (DTR5.3.1.1 (b))
-----------------------------------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise / Physical or cash Number of % of voting rights
instrument date (x) Conversion settlement (xii) voting rights
Period (xi)
------------------------------- ------------------------- -------------------------- ----------------- -------------- --------------------------
SUBTOTAL 8.B.2
----------------- -------------- --------------------------
9. Information in relation to the person subject to
the notification obligation (please mark the applicable
box with an "X")
Person subject to the notification obligation is not
controlled by any natural person or legal entity and
does not control any other undertaking (s) holding
directly or indirectly an interest in the (underlying)
issuer (xiii)
Full chain of controlled undertakings through which
the voting rights and / or the financial instruments
are effectively held starting with the ultimate controlling
natural person or legal entity (xiv) (please add additional
rows as necessary) X
----------------------------------------------------------------- ------------------------------
% of voting rights
% of voting rights if it through financial
equals or is higher instruments if it equals Total of both if it
than the notifiable or is higher than the equals or is higher
Name (xv) threshold notifiable threshold than the notifiable threshold
------------ ------------------------ ------------------------- ------------------------------
Abingworth
LLP 4.75 4.75
------------ ------------------------ ------------------------- ------------------------------
Abingworth less than 0.01 less than 0.01
Bioventures
VI LP
------------ ------------------------ ------------------------- ------------------------------
10. In case of proxy voting, please identify:
-------------------------------------------------------------------------------------------------
Name of the proxy holder
-------------------------------------- ---------------------------------------------------------
The number and% of voting rights held
-------------------------------------- ---------------------------------------------------------
The date until which the voting rights
will be held
-------------------------------------- ---------------------------------------------------------
11. Additional information (xvi)
-------------------------------------------------------------------------------------------------
Abingworth Bioventures VI LP (which holds 19,660,001
shares in the company (4.75%)) is managed by Abingworth
LLP.
-------------------------------------------------------------------------------------------------
Place of completion Outside a trading venue
------------------- -----------------------
Date of completion 30 July 2020
------------------- -----------------------
For further information, please contact:
Verona Pharma plc Tel: +44 (0) 20 3283
4200
David Zaccardelli, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications
N + 1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0) 20 7496
3000
Aubrey Powell / George Tzimas / Iqra Amin (Corporate
Finance)
Tom Salvesen (Corporate Broking)
(END) Dow Jones Newswires
July 30, 2020 05:52 ET (09:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
